As part of the September issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews Associate Editor Marcus Mall about neutrophil-derived biomarkers in bronchiectasis, as discussed in his review article in this issue of the ERJ: https://doi.org/10.1183/13993003.00081-2025

Correction: At 5 min 54 s in this podcast, in response to a question from D. Sin regarding the dosing of azithromycin, M. Mall mistakenly replied that “For the immunomodulatory effects, it would be a standard long-term therapy with a three times per day regimen.” He meant to say “three times per week”. We apologise for this error.

Cite this podcast as: ERJ Podcast September 2025: Neutrophil-derived biomarkers in bronchiectasis. Eur Respir J 2025; 55: 25E6603. [https://doi.org/10.1183/13993003.E6603-2025]

ERS Publications Podcasts

ERS Publications Podcasts

ERJ Podcast September 2025: Neutrophil-derived biomarkers in bronchiectasis

SEP 26, 202511 MIN
ERS Publications Podcasts

ERJ Podcast September 2025: Neutrophil-derived biomarkers in bronchiectasis

SEP 26, 202511 MIN

Description

As part of the September issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews Associate Editor Marcus Mall about neutrophil-derived biomarkers in bronchiectasis, as discussed in his review article in this issue of the ERJ: https://doi.org/10.1183/13993003.00081-2025 Correction: At 5 min 54 s in this podcast, in response to a question from D. Sin regarding the dosing of azithromycin, M. Mall mistakenly replied that “For the immunomodulatory effects, it would be a standard long-term therapy with a three times per day regimen.” He meant to say “three times per week”. We apologise for this error. Cite this podcast as: ERJ Podcast September 2025: Neutrophil-derived biomarkers in bronchiectasis. Eur Respir J 2025; 55: 25E6603. [https://doi.org/10.1183/13993003.E6603-2025]